DS
SPRY icon

David Shaw’s ARS Pharmaceuticals SPRY Stock Holding History

David Shaw’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,873
Closed -$95.3K – 5197
2026
Q1 		$95.3K Sell
11,873
-14,654
-55% -$140K ﹤0.01% 4289
2025
Q4 		$309K Sell
26,527
-7,692
-22% -$74.8K ﹤0.01% 4132
2025
Q3 		$344K Sell
34,219
-23,230
-40% -$333K ﹤0.01% 4042
2025
Q2 		$1M Buy
57,449
+23,652
+70% +$341K ﹤0.01% 3236
2025
Q1 		$425K Sell
33,797
-42,935
-56% -$517K ﹤0.01% 3584
2024
Q4 		$810K Sell
76,732
-3,816
-5% -$53.4K ﹤0.01% 3330
2024
Q3 		$1.17M Buy
80,548
+12,315
+18% +$146K ﹤0.01% 3162
2024
Q2 		$581K Buy
68,233
+30,056
+79% +$267K ﹤0.01% 3532
2024
Q1 		$390K Buy
+38,177
New +$285K ﹤0.01% 3602
2023
Q2 		– Sell
-24,302
Closed -$158K – 4532
2023
Q1 		$158K Sell
24,302
-19,396
-44% -$149K ﹤0.01% 3943
2022
Q4 		$373K Buy
43,698
+14,409
+49% +$93.5K ﹤0.01% 3995
2022
Q3 		$155K Sell
29,289
-62,834
-68% -$310K ﹤0.01% 4537
2022
Q2 		$391K Sell
92,123
-95,199
-51% -$332K ﹤0.01% 4236
2022
Q1 		$658K Sell
187,322
-62,694
-25% -$273K ﹤0.01% 4204
2021
Q4 		$1.67M Sell
250,016
-564
-0.2% -$4.58K ﹤0.01% 3521
2021
Q3 		$2.5M Buy
250,580
+40,453
+19% +$998K ﹤0.01% 2826
2021
Q2 		$6.49M Buy
210,127
+4,714
+2% +$151K 0.01% 1835
2021
Q1 		$8.96M Buy
+205,413
New +$9.72M 0.01% 1435

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

David Shaw's SPRY Position: Q2 2026 in Review

David Shaw sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 11,873 shares — an estimated $95.3K sold.

David Shaw first reported a position in SPRY in Q1 2021 and held it in 18 quarters. The position peaked at $8.96M in Q1 2021. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • David Shaw reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • David Shaw sold 11,873 ARS Pharmaceuticals shares in Q2 2026, an estimated $95.3K.
  • David Shaw first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 18 quarters.
  • David Shaw's ARS Pharmaceuticals position peaked at $8.96M in Q1 2021.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.